UPB Upstream Bio Inc Forecast, Technical & Fundamental Analysis
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders... Show more
UPB is expected to report earnings to rise 18.67% to -88 cents per share on August 12
Q2'26
Est.
$-0.89
Q1'26
Beat
by $0.10
Q4'25
Beat
by $0.06
The last earnings report on May 13 showed earnings per share of -75 cents, beating the estimate of -85 cents. With 133.22K shares outstanding, the current market capitalization sits at 396.18M.
A.I.dvisor indicates that over the last year, UPB has been loosely correlated with IRON. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if UPB jumps, then IRON could also see price increases.
Momentum Indicator for UPB turns positive, indicating new upward trend
UPB saw its Momentum Indicator move above the 0 level on June 25, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator turned positive. In of the 23 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for UPB just turned positive on June 23, 2026. Looking at past instances where UPB's MACD turned positive, the stock continued to rise in of 19 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where UPB advanced for three days, in of 87 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for UPB moved out of overbought territory on July 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 13 similar instances where the indicator moved out of overbought territory. In of the 13 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
UPB moved below its 50-day moving average on July 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UPB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
UPB broke above its upper Bollinger Band on July 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for UPB entered a downward trend on June 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.303) is normal, around the industry mean (22.746). P/E Ratio (0.000) is within average values for comparable stocks, (37.261). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.488). UPB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (119.048) is also within normal values, averaging (432.117).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. UPB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UPB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Upstream Bio (UPB) stock Forecast, Price Targets and Analysts Predictions - Tickeron.com
